Understanding the interplay between tumor, patient & therapy to achieve improved therapeutic outcomes.
Our data has been published in multiple peer-reviewed journals:
Presentations & Posters
We are committed to transparency and disseminating our research results within the scientific community. Here is the data we have showcased at international medical conferences:
Pre-treatment plasma proteomics-based predictive biomarkers for immune-related adverse events in non-small cell lung cancer
Impact of PROphet Assay in Changing Physicians' Therapeutic Decision-Making for Checkpoint Immunotherapy in NSCLC
PROPHETIC: Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti-Cancer Treatments
PROPHETIC is a prospective, multicenter, international study to develop an algorithm that predicts patient treatment outcomes. The algorithm serves as a treatment decision-making tool for physicians, specifically for stage IV non-small cell lung cancer (NSCLC) and malignant melanoma patients receiving anti-cancer treatments. Investigators also aim to identify the metabolic pathways that could lead to better therapeutic options.
This is not a therapeutic study in which a new treatment is tested. Patients receive standard-of-care treatment for their disease and undergo tests as usual for the full duration of this study. The study will enroll approximately 10,000 patients worldwide. Each will participate in the study for up to 5 years.
Identifying patients who will benefit from immunotherapy is still a major challenge in clinical oncology. The average response rate for these treatments is in the range of 20%; That is, approximately 1 in 5 patients respond positively to the treatment.
To avoid unnecessary treatment, delays in administration, adverse reactions and/or unnecessary costs, it is important to identify, in advance, patients who will respond to their proposed treatment plan. For some treatments, biomarkers can help predict response. But strong biomarkers are lacking for multiple cancer indications.
Studies conducted in the laboratory of Prof. Yuval Shaked of the Technion, Israel Institute of Technology, have shown that the body has a biological reaction to any administered anti-cancer treatment, including immunotherapy, chemotherapy, radiation, surgery, and targeted drugs. During this phenomenon which we call the “host response,” many different biological compounds, including proteins that may interfere with the treatment’s proper function, are secreted into the bloodstream.
In this study, we are analyzing the “host response” profile of the treated patient in order to predict whether they will benefit from their given treatment. Blood samples are taken from patients before and during their therapy plans, and analyzed. The analysis is used towards further developing our PROphet® platform.
Stage IV Non-Small Cell Lung Cancer
Stage III and IV Malignant Melanoma
Stage IV Small Cell Lung Cancer